Bristol Myers Squibb Raises 2026 Revenue Forecast, Lowers EPS Outlook Amid Strong Growth of Newer Drugs

Bristol Myers Squibb (NYSE: BMY) updated its full-year 2026 guidance this week, upwardly revising its revenue forecast while lowering its earnings per share outlook due to a significant acquisition-related charge.

In its third-quarter financial report, released on October 29, 2026, the company raised its full-year revenue forecast, highlighting strong performance from its newer product portfolio. At the same time, the company downgraded its adjusted EPS projection for 2026, citing a sizable acquisition-related charge as the primary cause. The revenue outlook increase reflects continued commercial momentum of recent launches, while the EPS reduction underscores the non-recurring impact of M&A integration costs.

According to Reuters, the full-year revenue forecast for 2026 was lifted, though EPS guidance was reduced on account of acquisition expenses. The report emphasized that the decision to adjust EPS was driven by integration and amortization charges tied to prior acquisitions. Meanwhile, the Wall Street Journal similarly noted the revenue upgrade but stressed the EPS cut due to one‑off charges related to the company’s acquisition activity.

These developments come as Bristol Myers Squibb shares have shown resilience. As of November 4, 2026, the stock was trading at $64.19, reflecting a 1.58% gain. The revised guidance may explain short‑term investor optimism, while the lowered EPS raises questions about underlying profitability trends once non‑recurring charges are normalized.

Why This Matters

By raising its revenue outlook, Bristol Myers Squibb signals continued strength in its portfolio of recently approved therapies—critical for long‑term growth in a competitive biopharmaceutical landscape. At the same time, investors must consider that adjusted EPS expectations have been trimmed, which may temper near‑term earnings sentiment despite revenue upside.

Looking ahead, stakeholders will be watching for further details on the acquisition-related charges and how they impact free cash flow and future margins. Sustained performance from new therapies will be essential to offset integration costs and support long-term value creation.

Summary

• Bristol Myers Squibb raised its full-year 2026 revenue forecast following robust newer drug sales.
• EPS guidance for 2026 was lowered due to a significant acquisition-related charge.
• The stock, priced at $64.19 as of November 4, 2026, reflects mixed investor reactions to these contrasting developments.
• Going forward, observers will monitor therapy performance and the duration of acquisition-related expense impacts.